Metastatic Squamous Neck Cancer

Metastatic Squamous Neck Cancer Article

000 Americans will develop cancer of the head and neck cancer sites include a lump or sore throat that of developing a new cancer, usually

Metastatic Squamous Neck Cancer News

Cytokinetics Reports Data for Ispinesib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Data Presented at Annual Meeting of the European Society of Medical Oncology SOUTH SAN FRANCISCO, Calif., Oct. 2 /PRNewswire-FirstCall/ - Cytokinetics, Incorporated announced results from a planned interim analysis following Stage 1 of a two-stage Phase II clinical trial of ispinesib administered

FDA Approves ERBITUX for Treatment of Head and Neck Cancer; First and Only Approved Monoclonal Antibody for Squamous Cell Carcinoma of the Head and Neck.

NEW YORK & PRINCETON, N.J. - ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved ERBITUX(R) (Cetuximab), an IgG1 monoclonal antibody, for use in the treatment of squamous cell

Independent Clinical Review of Phase III Trial Shows Erbitux and Radiation Control Spread of Advanced Squamous Cell Cancer of the Head and Neck Better Than Radiation Alone; Primary and Secondary Study Endpoints Met with Statistical Significance.

NEW YORK - ImClone Systems Incorporated (NASDAQ: IMCL) announced today that an Independent Clinical Review Committee (ICRC) analysis of a Phase III study (IMCL-9815) of Erbitux(R) (Cetuximab) in combination with radiation in first-line squamous cell carcinoma of the head and neck (SCCHN) confirmed

Management of the unknown primary in patients with metastatic cancer of the head and neck.

Abstract The evaluation of the patient with metastatic cervical lymph node squamous cell carcinoma and an unknown primary tumor frequently involves the use of guided biopsies as a diagnostic tool. This study was performed to assess the effectiveness of these biopsies. Using a retrospective chart

Gemcitabine and cisplatin in patients with locally advanced, recurrent, or metastatic head and neck cancer: results of a Phase II trial.

ABSTRACT Objectives: Determine the response to concurrent administration of gemcitabine plus cisplatin in patients with metastatic or locally advanced recurrent squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods: Patients with metastatic or locally advanced SCCHN that is